Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children

摘要: ummary Background Saccharomyces boulardii is a non-pathogenic probiotic yeast considered useful against enteropathogens. Aim To assess the effectiveness of S. in treating acute infectious diarrhoea children. Methods The following electronic databases were searched through August 2006 for studies relevant to and boulardii: MEDLINE, EMBASE, CINAHL The Cochrane Library; additional references obtained from reviewed articles. Only randomized-controlled trials included. Results Five (619 participants) met inclusion criteria. Combined data four showed that significantly reduced duration compared with control. pooled weighted mean difference was −1.1 days (95% CI: −1.3 −0.8) fixed model remained significant random effect model. Saccharomyces risk on 3, 6 7. Also lasting >7 days group vs. control (1 RCT, n = 88, RR 0.25, 95% 0.08–0.83; NNT 5, 3–20). Conclusions There exists moderate clinical benefit therapy otherwise healthy infants children gastroenteritis, mainly shorter diarrhoea. However, these results should be interpreted caution due methodological limitations included studies.